by Richard Daverman, PhD
June 23, 2012 -- Quintiles will invest $14 million to build a regional headquarters for China in Shanghai’s Feng Lin Science Park; Ascepion Pharma of Suzhou out-licensed worldwide rights for an oncology drug candidate to Debiopharm Group™ of Switzerland; Gentris signed a MOU with the Shanghai Institutes of Preventive Medicine (SIPM) to collaborate on genomic biomarkers; NeoStem will divest its 51% interest in its China subsidiary, Suzhou Erye Pharmaceutical, for $12.3 million in cash; China Medical Technologies bondholders filed a petition to force the company into bankruptcy after it missed a payment; and Xiamen Innovax Biotech expects to launch Hecolin, its hepatitis E vaccine, in China later this year. More details….
Stock Symbols: (NYSE: NBS) (OTCBB: CMEDY)
